Strategic Blueprint, LLC Cyma Bay Therapeutics, Inc. Transaction History

Strategic Blueprint, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	SELL	$12.63 - $24.47 $12,630 - $24,470	-1,000 Reduced 5.95%	15,800 $373,000
Q3 2023 Oct 18, 2023	BUY	$10.86 - $17.62 $10,860 - $17,620	1,000 Added 6.33%	16,800 $250,000
Q1 2023 Apr 28, 2023	SELL	$5.88 - $9.59 $14,112 - $23,016	-2,400 Reduced 13.19%	15,800 $137,000
Q3 2022 Nov 08, 2022	BUY	$2.77 - $4.25 $50,414 - $77,350	18,200 New	18,200 $64,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Strategic Blueprint, LLC, based on Form 13F filings with the SEC.

Stay updated on Strategic Blueprint, LLC with notifications on news.